SecBot SecBot
Biotech Drug Report Generated Nov 3, 2026

BAT

EBS·Emergent BioSolutions Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and marketed since 2013.
Why 4/10
BAT is already FDA-approved (since 2013) and commercially marketed with no pending regulatory decision or pivotal readout scheduled. The next hard catalyst would be a major U.S. government contract award or modification, which is not a dated binary event. Per the impact score rubric, an approved drug with no pending regulatory decision scores 3-5, and BAT is one of several products in Emergent's diversified portfolio, not the sole value driver.
Actionable Insight NEUTRAL

BAT is an already-approved, marketed product with no pending FDA decision. The next catalyst for Emergent is not BAT-specific but rather the pace of U.S. government contract awards and international orders, which drive lumpy quarterly revenue. Watch for further ASPR contract modifications or international BAT orders, as well as the company's Q4 2026 earnings for updates on the full-year guidance trajectory.

Price Chart

Loading chart...

Executive Summary

BAT (Botulism Antitoxin Heptavalent) is an equine-derived antitoxin that neutralizes all seven known botulinum neurotoxin serotypes. It was originally developed by Cangene Corporation and approved by the FDA in March 2013 under the Animal Rule as a biodefense medical countermeasure. Emergent BioSolutions (NYSE: EBS), which acquired Cangene, now manufactures and markets BAT exclusively to government stockpiles. BAT is the only FDA-approved product for treating symptomatic botulism in adults across all serotypes. Revenue is lumpy and tied to U.S. government procurement contracts; a $64.5 million ASPR contract modification was awarded in May 2026. In Q3 2026, BAT sales fell sharply due to timing of government deliveries, contributing to a 52% overall revenue decline for Emergent. The drug has no pending FDA regulatory decision, making it a stable but low-growth asset within Emergent's broader biodefense portfolio.

How It Works

BAT is an antitoxin made from antibodies harvested from horses that have been immunized against botulinum toxins. When injected into a patient with botulism, these antibodies bind to and neutralize the free-floating botulinum nerve toxins in the bloodstream, preventing them from causing further damage. It covers all seven known botulinum toxin types (A through G). It does not reverse damage already done by the toxin, so it must be given as early as possible after symptoms appear.

Trial Status

BAT was approved by the FDA on March 22, 2013, under the Animal Rule (efficacy established in animal models). It is also approved by Health Canada. No active clinical trials are ongoing for the approved indication; the drug is commercially available and distributed through the CDC for use in suspected or confirmed botulism cases.

The Two-Sided Case

▲ Bull Case4
BAT is the only FDA-approved product for treating symptomatic botulism across all seven botulinum neurotoxin serotypes (A through G) in adults and pediatric patients, giving it a unique, non-substitutable position in U.S. biodefense stockpiles.
Emergent received a $64.5 million contract modification from ASPR in May 2026 for BAT supply, demonstrating continued U.S. government commitment to stockpiling the product.
BAT is also approved by Health Canada, and the company reported an increase in international BAT sales in Q3 2026, partially offsetting lower U.S. government orders.
Analyst consensus is bullish: 5 buy/strong buy ratings vs 1 hold and 1 sell, with a mean price target of $11 (61.5% implied upside from the $6.81 close).
▼ Bear Case4
BAT revenue is inherently lumpy and unpredictable, driven entirely by U.S. government and international procurement timing, not recurring commercial demand. Q3 2026 Other Product sales (including BAT) fell 87% YoY to $7.6M due to timing of USG BAT deliveries.
Emergent's overall financials are deteriorating: Q3 2026 total revenue fell 52% YoY, the company cut full-year 2026 guidance for the second time, and GAAP net loss was $32.7M versus net income of $51.2M a year earlier.
BAT faces no direct FDA-approved competitor for adult botulism, but the addressable market is tiny (botulism is rare) and entirely government-procurement driven, limiting revenue growth potential.
CFO retirement and interim CFO appointment add leadership uncertainty during a restructuring phase.

Upcoming Catalysts

  • U.S. government (ASPR) contract modifications or new awards for BAT stockpile replenishment
  • International government BAT orders (the company noted increased international sales in Q3 2026)
  • Emergent Q4 2026 earnings (early 2027) for BAT revenue and full-year 2027 guidance

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Emergent BioSolutions Inc. 8-K EBS ·Originating report

Sources · 10

Hover a chip for the title
1 en.wikipedia.org2 investors.emergentbiosolutions.com3 biospace.com4 sec.gov5 tradingkey.com6 globalbiodefense.com7 fda.gov8 morningstar.com9 benzinga.com10 emergentbiosolutions.com